Selumetinib Sulfate Patent Expiration
Selumetinib Sulfate is Used for treating symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1 (NF1) aged 2 years and older. It was first introduced by Astrazeneca Pharmaceuticals Lp
Selumetinib Sulfate Patents
Given below is the list of patents protecting Selumetinib Sulfate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Koselugo | US11813246 | Pharmaceutical composition | Mar 26, 2029 | Astrazeneca |
| Koselugo | US7425637 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Mar 13, 2025 | Astrazeneca |
| Koselugo | US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Mar 13, 2025 | Astrazeneca |
| Koselugo | US9156795 | Hydrogen sulfate salt | Dec 12, 2026 | Astrazeneca |
| Koselugo | US9562017 | Hydrogen sulfate salt | Dec 12, 2026 | Astrazeneca |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳